Emerging infections: surveillance, epidemiology and pathogenesis

NIH Pandemic-Era Grants

Pandemic Era Grants

2022

↗ Live URL (may be dead)

Document text

Principal Investigator: DAVID  WANG
Organization: WASHINGTON UNIVERSITY
Fiscal Year: 2022
Award: $247,061
Funding agency: National Institute of Allergy and Infectious Diseases

PROJECT SUMMARY
The incidence of tick-borne diseases has increased significantly over the past 25 years due to climate change,
shifting population demographics of both humans and ticks, and inadequate vector control. Including economic
and societal costs, it is estimated that tick-borne diseases costs between 50 and 100 billion dollars each year.
The Center for Disease Control and Prevention currently recognizes 18 different tick-transmitted pathogens in
the United States. This number is likely to rise as novel viruses and pathogens are being discovered each year.
One of these pathogens is Bourbon virus (BRBV), an emerging tick-borne RNA virus that can infect and cause
disease in humans. No antiviral therapies or vaccines are available, highlighting the need to develop
countermeasures against these life-threatening diseases. The primary objective of this application is to develop
an mRNA vaccine against BRBV, evaluate its efficacy in vivo in a mouse model of BRBV and determine the
mechanism of action. A secondary goal is to test different viral antigens and mRNA vaccine designs to improve
multivalent mRNA vaccines. Successful completion of the proposed studies will provide the preliminary data for
a R01 application aimed at developing a universal vaccine that confers protection against tick and tick-borne
pathogens in the United States.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><Address><Animal Model><Animal Models and Related Studies><Antibodies><Antibody Response><Antigens><Antisera><Antiviral Therapy><Arthropod Vectors><Assay><Attenuated><B burgdorferi><B. burgdorferi><Bioassay><Biologic Assays><Biological Assay><Borrelia burgdorferi><Borrelia burgdorferi sensu stricto><Borreliella burgdorferi><Bourbon virus><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CDC><COVID crisis><COVID epidemic><COVID pandemic><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 virus><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 pandemic><COVID19 public health crisis><COVID19 virus><Cellular Assay><Centers for Disease Control><Centers for Disease Control and Prevention><Centers for Disease Control and Prevention (U.S.)><CoV-2><CoV2><Cost of Illness><D pneumoniae><D. pneumoniae><Data><Diplococcus pneumoniae><Disease><Disease Costs><Disease model><Disorder><ELISA><ELISPOT><Enzyme-Linked Immunosorbent Assay><Epidemiology><Future><Glycoproteins><Goals><Health><Heartland virus><Human><Immune><Immune Sera><Immune response><Immunes><Immunity><Immunize><Immunological response><Incidence><Infection><Influenza Virus><Ixodida><Knowledge><Life><Lyme Borreliosis><Lyme Disease><Lyme Disease Spirochete><Meningitis><Messenger RNA><Mice><Mice Mammals><Modeling><Modern Man><Murine><Mus><Neisseria><Pathogenesis><Pneumococcus><Population><Powassan><Powassan virus><Process><Proteins><RNA Viruses><RNA vaccine><RNA-based vaccine><Rodent Model><S pneumoniae><S. pneumoniae><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 pandemic><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 pandemic><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Salivary Gland Proteins><Salivary Proteins><Scientist><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome related corona virus 2><Sickness Cost><Streptococcus pneumoniae><T cell response><T-Cells><T-Lymphocyte><T8 Cells><T8 Lymphocytes><Technology><Testing><Tick-Borne Diseases><Tick-Borne Encephalitis Virus><Tickborne Encephalitis Virus><Ticks><Transmission><United States><United States Centers for Disease Control><United States Centers for Disease Control and Prevention><Vaccine Antigen><Vaccine Design><Vaccines><Viral><Viral Antigens><Viral Envelope Proteins><Virus><Virus-like particle><Wuhan coronavirus><access to vaccination><access to vaccines><adaptive immunity><anti-viral therapy><cell assay><climate change><climatic changes><combat><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 virus><demographics><design><designing><develop a vaccine><develop vaccines><development of a vaccine><disorder model><economic cost><enzyme linked immunoassay><enzyme linked immunospot assay><epidemiologic><epidemiological><evaluate vaccines><global climate change><hCoV19><host response><immune serum><immune system response><immunogen><immunogenic><immunogenicity><immunoresponse><improved><in vivo><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><influenzavirus><lipid based nanoparticle><lipid nanoparticle><lyme spirochete><mRNA><mRNA vaccine><mRNA-based vaccine><model of animal><model organism><mouse model><murine model><nCoV2><neutralizing antibody><novel virus><pathogen><pathogenic virus><prevent><preventing><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><societal costs><thymus derived lymphocyte><tick bite><tick mediated transmission><tick transmission><tick transmitted><tick-borne><tick-borne illness><tick-borne pathogen><tick-borne virus><tickborne><tickborne disease><tickborne illness><tickborne pathogen><tickborne virus><transmission process><universal vaccine><vaccination access><vaccination availability><vaccine access><vaccine availability><vaccine development><vaccine evaluation><vaccine screening><vaccine testing><vector><vector control><viral infectious disease treatment><viral pathogen><virology><virus antigen><virus pathogen><virus-like nanoparticles><viruslike particle>